MDR504 hACE2-Fc

ACE2-Fc IgG1 fusion protein

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Link	Tested on	Impact factor	Notes	Publication date
Novel ACE2-IgG1 fusions with increased activity against SARS-CoV-2 Preprint Animal model	VERO E6 cell cultures		Prophylactic administration of MDR504 significantly attenuated SARS-CoV2 infection in a murine model.	Jun/15/2020

Link	Publication date
ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2.	Dec/20/2021